RxDoctor Payments Data

Vernon Peryea, OD

Optometrist · Peekskill, NYNPI 1376505396

Payments from drug & device makers

$8,207in general payments, 2019–2025

Across 347 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ABB Con-cise Optical Group LLC$2K
  • Bausch & Lomb Americas Inc.$1K
  • Alcon$1K
  • Coopervision Inc.$798
  • AbbVie$515
  • Sun Pharmaceutical Industries Inc.$501
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$8,182100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,207 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$134,116
Medicare patients
522
Services billed
1,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast106$114,382
RestasisCyclosporine64$78,266
RocklatanNetarsudil Mesylat/Latanoprost38$25,488
LumiganBimatoprost28$17,723
Brimonidine Tartrate44$10,854
Latanoprost481$8,779
VyzultaLatanoprostene Bunod14$8,721
Cyclosporine26$7,607
Timolol Maleate134$5,998
Travoprost12$5,912
CombiganBrimonidine Tartrate/Timolol18$4,906
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$3,905
Prednisolone Acetate63$3,587
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat123$2,209
Dorzolamide-TimololDorzolamide/Timolol/Pf12$2,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$1,344$123,103120 claims
AbbVieRestasis, Lumigan, Combigan$515$100,895110 claims
Aerie Pharmaceuticals, Inc.Rocklatan$260$25,48838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.

Other optometrist in Peekskill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →